Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Femiflor
- Development stage
- Unknown
- Lead developer
- Laboratoires Élerté
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Femiflor is an oral dietary supplement developed by Laboratoires Élerté, specifically formulated to support gynecological health by maintaining the balance of the vaginal microbiota. It contains a combination of two probiotic strains, *Lactobacillus rhamnosus* Rosell-11 and *Lactobacillus helveticus* Rosell-52, along with Vitamin B2 (riboflavin). These probiotics work by colonizing the intestinal tract and subsequently the vaginal environment, where they produce lactic acid to maintain an acidic pH and competitively inhibit the growth of pathogens such as *Candida albicans* and bacteria associated with bacterial vaginosis. Vitamin B2 is included to support the maintenance of healthy mucous membranes. Femiflor is primarily used as a complementary approach to prevent or manage vaginal dysbiosis and recurrent gynecological infections.
- Brand names
- Femiflor
Beyond the preview
Go deeper on Femiflor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Femiflor.